Skip to main content
. Author manuscript; available in PMC: 2012 Nov 3.
Published in final edited form as: Nature. 2012 Mar 29;485(7396):62–68. doi: 10.1038/nature11030

Figure 1. SR9011 and SR9009 are synthetic REV-ERB agonists with activity in vivo.

Figure 1

a, Chemical structures of SR9011 and SR9009. b, GAL4-REV-ERBα and GAL4-REVERBβ cotransfection assays in HEK293 cells illustrating the activity of SR9011 and 9009 and comparing the activity to GSK4112. c, Cotransfection assay in HEK293 cells with full-length REV-ERBα and a luciferase reporter driven by the Bmal1 promoter. d, Bioluminescence record from a Per2LUC SCN treated with 5 μM SR9011 as indicated by the bar. The right panels display the period and amplitude of the oscillations prior to, during, and after treatment with SR9011. e, Expression of REV-ERB responsive genes after treatment with various doses of SR9011 or 100 mg/kg of SR9009 (i.p., b.i.d.) for 6-days. * indicates p<0.05. ** indicates p<0.05 vs. before SR9011 and during SR9011 treatment. Error bars indicate mean ± s.e.m. and n=6.